Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants

Taysha Gene Therapies, Inc.

Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.
Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).
Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.
Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.
Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.